European public procurement and grants data from official registers · Data as of 18 November 2026; updated daily.

Tenders

Oncology drug tenders in Greece

Oncology drug tenders in Greece: 816 listed on GranTender since 2024. The median awarded contract value is about €7,300 (418 contracts with a stated value). Buyers with the most tenders: JANSSEN-CILAG (3), ROCHE (2) and IPSEN ΕΠΕ (2); suppliers with the most contract awards: JANSSEN-CILAG (136), ASTRAZENECA ΑΕ (73) and UCB Α.Ε. (58). Sources: KIMDIS (ΚΗΜΔΗΣ) and TED. In 2025 the median contract value was €6,500. Data as of 18 November 2026; updated daily.

Tenders
816
Open tenders
0
Awards
804
Awarded value awarded
€6,336,219
Awarded value contract
€4,358,309
Median contract value awarded
≈ €7,300
Median contract value contract
≈ €7,300
Average bids per contract
1.1
Tenders in 2025
340 +6% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

No records yet.

Latest tenders

TenderBuyerEstimated valueStatusPublished
ΣΥΜΒΑΣΗ ΥΠ ΑΡΙΘΜ 151/2026 401 ΓΣΝΑ ΑΝΤΙΝΕΟΠΛΑΣΜΑΤΙΚΑ ΦΑΡΜΑΚΑΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded23 June 2026
ΠΡΟΣΚΛΗΣΗ ΥΠΟΒΟΛΗΣ ΠΡΟΣΦΟΡΑΣ ΥΠ’ΑΡΙΘΜ. Α-651/2026 (7300014396)ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€29,402,200Cancelled15 May 2026
401 ΓΣΝΑ Διακήρυξη του υπ΄ αριθμ.23/26 Ηλεκτρονικού Διαγ. με Ανοικτή Διαδικασία του άρθρου 27ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€94,338Cancelled11 May 2026
401 ΓΣΝΑ Διακήρυξη του υπ΄ αριθμ.24/26 Ηλεκτρονικού Διαγ. με Ανοικτή Διαδικασία του άρθρου 27ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€132,070Awarded11 May 2026
ΣΥΜΒΑΣΗ ΥΠ ΑΡΙΘΜ 407/2025 401 ΓΣΝΑ ΑΝΤΙΝΕΟΠΛΑΣΜΑΤΙΚΑ ΦΑΡΜΑΚΑΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded4 November 2025
ΣΥΜΒΑΣΗ ΥΠ ΑΡΙΘΜ 393/2025 401 ΓΣΝΑ ΑΝΟΣΟΚΑΤΑΣΤΑΛΤΙΚΑ ΦΑΡΜΑΚΑΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded17 October 2025
ΔΙΑΚΗΡΥΞΗ ΥΠ΄ΑΡΙΘΜ. 29/2025 (ΑΝΟΣΟΚΑΤΑΣΤΑΛΤΙΚΑ ΦΑΡΜΑΚΑ)ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€93,867Awarded21 August 2025
ΑΛΛΑ ΘΕΜΑΤΑ ΣΥΜΒΑΣΕΩΝ ΤΡΟΠΟΠΟΙΗΣΗ Νο 1 (Τ1) ΔΙΑΚΥΡΥΞΗ 27/2025 401 ΓΣΝΑ (ΕΣΗΔΗΣ:378266) ΑΝΤΙΝΕΟΠΛ.ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€132,030Closed30 July 2025
ΔΙΑΚΗΡΥΞΗ 27/2025 401 ΓΣΝΑ (ΕΣΗΔΗΣ:378266) ΑΝΤΙΝΕΟΠΛΑΣΜΑΤΙΚΑ ΦΑΡΜΑΚΑΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€132,030Cancelled22 July 2025
Διακήρυξη Ηλεκτρονικού Διαγωνισμού Ανοικτής Διαδικασίας ΑΔ_28/2025ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€95,315Awarded27 March 2025
Σύμβαση 35/24 για την Προμήθεια ΦΙΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded23 January 2025
Σύμβαση 36/24 για την Προμήθεια ΦΙΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded23 January 2025
Σύμβαση 33/24 για την Προμήθεια ΦΙΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded23 January 2025
Σύμβαση 31/24 για την Προμήθεια Φ.Ι 251ΓΝΑΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded16 January 2025
Σύμβαση 32/24 για την Προμήθεια ΦΙΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded16 January 2025
Σύμβαση 30/24 για την Προμήθεια ΦΙΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded16 January 2025
Σύμβαση 34/24 για την Προμήθεια ΦΙΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded14 January 2025
Κατακύρωση των Αποτελεσμάτων της Ανοικτής Διαδικασίας με αριθμό 43/22ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded20 December 2024
401 ΓΣΝΑ ΠΡΟΣΚΛΗΣΗ ΥΠΟΒΟΛΗΣ ΠΡΟΣΦΟΡΑΣ (ROCHE HELLAS)ΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ€132,072Closed19 August 2024
ΣΥΜΒΑΣΗ ΥΠ ΑΡΙΘΜ 51/2024 401 ΓΣΝΑ ΑΝΤΙΝΕΟΠΛΑΣΜΑΤΙΚΑ ΦΑΡΜΑΚΑΥΠΟΥΡΓΕΙΟ ΕΘΝΙΚΗΣ ΑΜΥΝΑΣ—Awarded16 April 2024

Competition and prices

In 2025, half of the contracts were worth between €4,100 and €12,000, with a median of €6,500 (177 contracts with a stated contract value). Compared with 2024, in 2025 the median value fell 11%. The usual procedures: direct award (96%), open procedure (3%), negotiation without a call for competition (0%) — of 816 tenders with a stated procedure.

The most contracts went to JANSSEN-CILAG (136), ASTRAZENECA ΑΕ (73) and UCB Α.Ε. (58) — together 33% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
2024300€7,300€4,300 – €9,700——
2025342€6,500 (contract value)€4,100 – €12,000——
2026 (so far)141€11,000€5,500 – €15,000——
All years804€7,300€4,100 – €12,000——

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

In the last 12 months, 0 companies won their first contract in our records here — 0% of the 150 contracts (our records start on 1 January 2024).

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33652000 Antineoplastic and immunomodulating agents

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Oncology and immunomodulating drugs in neighbouring countries

Today, 2 tenders in the same niche are open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Market reports

Oncology and immunomodulating drugs by city

Oncology and immunomodulating drugs in other countries

Oncology and immunomodulating drugs across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Where can I find oncology drug tenders in Greece?
GranTender lists them in one place, from KIMDIS (ΚΗΜΔΗΣ) and TED, with their buyers, winners and contract values. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most oncology drug tenders in Greece?
By number of contracts won: JANSSEN-CILAG (136), ASTRAZENECA ΑΕ (73), UCB Α.Ε. (58).
Which buyers publish the most oncology drug tenders in Greece?
By number of tenders: JANSSEN-CILAG (3), ROCHE (2), IPSEN ΕΠΕ (2).
Which CPV codes belong to “Oncology and immunomodulating drugs”?
33652000 Antineoplastic and immunomodulating agents; plus tenders without a usable CPV code whose title names the topic.
How much are contracts for oncology drug tenders in Greece worth?
In 2025, half of the contracts were worth between €4,100 and €12,000, with a median of €6,500 (177 contracts with a stated contract value). Compared with 2024, in 2025 the median value fell 11%.
Which procedures are used for oncology drug tenders in Greece?
The usual procedures: direct award (96%), open procedure (3%), negotiation without a call for competition (0%) — of 816 tenders with a stated procedure.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.